Lexaria Bioscience Provides Update on R&D Program Progress under License Agreement with Altria
Posted on Tuesday October 08, 2019

KELOWNA, BC / ACCESSWIRE / October 8, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide this update on the ongoing relationship and pursuit of innovation in oral, reduced risk nicotine consumer products using Lexaria's patented DehydraTECHTM technology, underway between Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc (NYSE:MO) ("Altria") and Lexaria's majority owned subsidiary Lexaria Nicotine LLC ("Lexaria Nicotine"). Most of the investigation and work within this first phase of the project is either complete or significantly underway, with one remaining aspect ready to commence imminently.

Peer Reviewed Clinical Journal Publishes Lexaria Bioscience's Human CBD Study Results
Posted on Tuesday September 17, 2019

KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / September 17, 2019 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that final study results of the 2018 human clinical study evaluating CBD delivery and effectiveness using its patented DehydraTECHTM powered TurboCBD™ capsules have been published in the peer reviewed medical journal, “Advances in Therapy”. Advances in Therapy focuses on clinical medicine and pharmaceutical research and has been published continually since 1984.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Featured in NetworkNewsAudio Publication Discussing Innovative Drug-Delivery Discovery
Posted on Friday September 06, 2019

While effectiveness of drugs is what most often captures the spotlight, that effectiveness is closely associated with the drug-delivery technology used, and innovation in this space may have a huge impact on how successful a drug can be. Lexaria Bioscience Corp.’s DehydraTECH(TM) may be the most novel form of drug delivery discovered in decades. Fatty acids used in the technology mask the smell and taste of the drug and potentially greatly reduce stomach upset.

Lexaria Bioscience Announces DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Disease Conditions
Posted on Tuesday August 27, 2019

KELOWNA, BC / ACCESSWIRE / August 27, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that it has received a new patent granted in Australia: #2016367037 / Grant Date August 15, 2019 - “Stable ready-to-drink beverage compositions comprising lipophilic active agents”. Lexaria’s patent portfolio has increased to 16 awarded patents protecting its DehydraTECH™ drug delivery platform, with 8 granted in the USA and 8 granted in Australia. This new Australian patent, together with Australian Patent #2016367036 “Methods for formulating orally ingestible compositions comprising lipophilic active agents” announced on August 15, 2019, are the first patents granted in Lexaria’s second and third patent families which differ from the Company’s original patent family, “Food and beverage compositions infused with lipophilic active agents and methods of use thereof” under which 14 of Lexaria’s patents have been granted.